{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:35:34Z","timestamp":1794609334437,"version":"4.9.1"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eclinm.2024.102581","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T19:46:19Z","timestamp":1712346379000},"page":"102581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Effect of antipsychotics and mood stabilisers on metabolism in\u00a0bipolar disorder: a network meta-analysis of randomised-controlled trials"],"prefix":"10.1016","volume":"71","author":[{"given":"Lingzhuo","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4702-4216","authenticated-orcid":false,"given":"Huaizhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-670X","authenticated-orcid":false,"given":"Shaohua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102581_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S2215-0366(18)30253-0","article-title":"Areas of uncertainties and unmet needs in bipolar disorders: clinical and research perspectives","volume":"5","author":"Bauer","year":"2018","journal-title":"Lancet Psychiatr"},{"key":"10.1016\/j.eclinm.2024.102581_bib3","first-page":"S80","article-title":"Bipolar disorder: disease burden","volume":"11","author":"Sajatovic","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.eclinm.2024.102581_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fpsyt.2020.00071","article-title":"Neuroinflammation in bipolar depression","volume":"11","author":"Benedetti","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.609487","article-title":"Concepts of neuroinflammation and their relationship with impaired mitochondrial functions in bipolar disorder","volume":"15","author":"Cyrino","year":"2021","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.eclinm.2024.102581_bib6","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12264-019-00403-7","article-title":"The relationship between neuroimmunity and bipolar disorder: mechanism and translational application","volume":"35","author":"Niu","year":"2019","journal-title":"Neurosci Bull"},{"key":"10.1016\/j.eclinm.2024.102581_bib7","doi-asserted-by":"crossref","first-page":"830748","DOI":"10.3389\/fnins.2022.830748","article-title":"Gut microbiota - a potential contributor in the pathogenesis of bipolar disorder","volume":"16","author":"Zhang","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1016\/j.eclinm.2024.102581_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41380-020-0831-4","article-title":"Advances toward precision medicine for bipolar disorder: mechanisms & molecules","volume":"26","author":"Haggarty","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14656566.2023.2194488","article-title":"An update on potential pharmacotherapies for cognitive impairment in bipolar disorder","volume":"24","author":"Johnson","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eclinm.2024.102581_bib10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14737175.2019.1562338","article-title":"Cortico-limbic connectivity as a possible biomarker for bipolar disorder: where are we now?","volume":"19","author":"Vai","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.eclinm.2024.102581_bib11","first-page":"74","article-title":"Molecular mechanisms of antipsychotics - their influence on intracellular signaling pathways, and epigenetic and post-transcription processes","volume":"31","author":"Rok-Bujko","year":"2022","journal-title":"Postep Psychiatr Neurol"},{"key":"10.1016\/j.eclinm.2024.102581_bib12","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/jama.2023.18588","article-title":"Diagnosis and treatment of bipolar disorder: a review","volume":"330","author":"Nierenberg","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102581_bib13","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","article-title":"Treatment of bipolar disorder","volume":"381","author":"Geddes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102581_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatr"},{"key":"10.1016\/j.eclinm.2024.102581_bib15","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s00406-002-0394-1","article-title":"Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review","volume":"252","author":"Koponen","year":"2002","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.eclinm.2024.102581_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0013-7006(05)82412-1","article-title":"[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management]","volume":"31","author":"Ruetsch","year":"2005","journal-title":"Encephale"},{"key":"10.1016\/j.eclinm.2024.102581_bib17","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40264-015-0339-z","article-title":"Drug-induced hyperglycaemia and diabetes","volume":"38","author":"Fathallah","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.eclinm.2024.102581_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.eclinm.2024.102581_bib19","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqad025","article-title":"Antipsychotic-induced alterations in lipid turnover","volume":"164","author":"Pereira","year":"2023","journal-title":"Endocrinology"},{"key":"10.1016\/j.eclinm.2024.102581_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1600-0447.1979.tb06969.x","article-title":"Lithium treatment and glucose tolerance in manic-melancholic patients","volume":"59","author":"Vendsborg","year":"1979","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.eclinm.2024.102581_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12011-014-9952-4","article-title":"Could selenium administration alleviate the disturbances of blood parameters caused by lithium administration in rats?","volume":"158","author":"Kielczykowska","year":"2014","journal-title":"Biol Trace Elem Res"},{"key":"10.1016\/j.eclinm.2024.102581_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S0004-27302012000300001","article-title":"Endocrine disturbances related to the use of lithium","volume":"56","author":"Giusti","year":"2012","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"10.1016\/j.eclinm.2024.102581_bib23","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S146114570500622X","article-title":"Lithium induces phosphoglucomutase activity in various tissues of rats and in bipolar patients","volume":"9","author":"Csutora","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1620\/tjem.213.79","article-title":"Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder","volume":"213","author":"Aliyazicioglu","year":"2007","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.eclinm.2024.102581_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/00048674221077619","article-title":"Lithium plus antipsychotics or anticonvulsants for bipolar disorder: comparing clinical response and metabolic changes","volume":"57","author":"Kohler-Forsberg","year":"2023","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.573479","article-title":"Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness","volume":"11","author":"Mazereel","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.eclinm.2024.102581_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","article-title":"Network meta-analysis: an introduction for clinicians","volume":"12","author":"Rouse","year":"2017","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.eclinm.2024.102581_bib29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2024.102581_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jad.2020.03.030","article-title":"Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis","volume":"269","author":"Bahji","year":"2020","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.eclinm.2024.102581_bib31","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/nep.13709","article-title":"Intention to treat and per protocol analysis in clinical trials","volume":"25","author":"Tripepi","year":"2020","journal-title":"Nephrology"},{"key":"10.1016\/j.eclinm.2024.102581_bib32","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102581_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/eb-2015-102088","article-title":"A\u00a0primer on network meta-analysis with emphasis on mental health","volume":"18","author":"Mavridis","year":"2015","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.eclinm.2024.102581_bib34","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1017\/S0033291718001071","article-title":"Treatments for bulimia nervosa: a network meta-analysis","volume":"48","author":"Slade","year":"2018","journal-title":"Psychol Med"},{"key":"10.1016\/j.eclinm.2024.102581_bib35","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"10.1016\/j.eclinm.2024.102581_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.eclinm.2024.102581_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/biomet\/asz002","article-title":"Multivariate output analysis for Markov chain Monte Carlo","volume":"106","author":"Vats","year":"2019","journal-title":"Biometrika"},{"key":"10.1016\/j.eclinm.2024.102581_bib38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1528-1167.2010.02915.x","article-title":"Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis","volume":"52","author":"Rheims","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eclinm.2024.102581_bib39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A\u00a0meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/JCP.0000000000000155","article-title":"Statistics commentary series: commentary #3--last observation carried forward","volume":"34","author":"Streiner","year":"2014","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaac.2021.03.021","article-title":"Systematic review and network meta-analysis: efficacy and safety of second-generation antipsychotics in youths with bipolar depression","volume":"61","author":"DelBello","year":"2022","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ph14030238","article-title":"Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences","volume":"14","author":"Carli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.eclinm.2024.102581_bib43","doi-asserted-by":"crossref","first-page":"104266","DOI":"10.1016\/j.neubiorev.2021.07.011","article-title":"Lithium therapy and weight change in people with bipolar disorder: a systematic review and meta-analysis","volume":"134","author":"Gomes-da-Costa","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.eclinm.2024.102581_bib44","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1060028019892644","article-title":"Esketamine: a novel option for treatment-resistant depression","volume":"54","author":"Bozymski","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.eclinm.2024.102581_bib45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1089\/cap.2014.0166","article-title":"Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder","volume":"25","author":"Kowatch","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib46","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2217\/pgs.15.55","article-title":"Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children","volume":"16","author":"Devlin","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.eclinm.2024.102581_bib47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1089\/cap.2013.0116","article-title":"Metabolic effects of antipsychotics in prepubertal children: a retrospective chart review","volume":"24","author":"Ebert","year":"2014","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatr"},{"key":"10.1016\/j.eclinm.2024.102581_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eclinm.2024.102581_bib50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00204-020-02963-4","article-title":"Antidepressants- and antipsychotics-induced hepatotoxicity","volume":"95","author":"Todorovic Vukotic","year":"2021","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.eclinm.2024.102581_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tem.2019.01.003","article-title":"Antipsychotics promote metabolic disorders disrupting cellular lipid metabolism and trafficking","volume":"30","author":"Vantaggiato","year":"2019","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.eclinm.2024.102581_bib52","first-page":"6","article-title":"The association between leptin and adiponectin, and metabolic syndrome components and serum levels of lipid peroxidation in bipolar disorder patients treated with lithium and valproic acid","author":"Dolab","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.eclinm.2024.102581_bib53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11373-008-9261-z","article-title":"Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond","volume":"15","author":"Lu","year":"2008","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.eclinm.2024.102581_bib54","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","article-title":"Lithium toxicity profile: a systematic review and meta-analysis","volume":"379","author":"McKnight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102581_bib55","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.psyneuen.2016.04.013","article-title":"Leptin serum concentrations are associated with weight gain during lithium augmentation","volume":"71","author":"Ricken","year":"2016","journal-title":"Psychoneuroendocrino"},{"key":"10.1016\/j.eclinm.2024.102581_bib56","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.euroneuro.2021.09.007","article-title":"A GWAS top hit for circulating leptin is associated with weight gain but not with leptin protein levels in lithium-augmented patients with major depression","volume":"53","author":"Bopp","year":"2021","journal-title":"Eur Neuropsychopharm"},{"key":"10.1016\/j.eclinm.2024.102581_bib57","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4088\/JCP.14m09642","article-title":"Bilirubin concentration correlates with positive symptoms in patients with schizophrenia","volume":"77","author":"Widschwendter","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.9758\/cpn.2017.15.2.153","article-title":"Relationship between serum bilirubin levels and metabolic syndrome in patients with schizophrenia spectrum disorders","volume":"15","author":"Karadag","year":"2017","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.eclinm.2024.102581_bib59","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eclinm.2024.102581_bib60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000117586","article-title":"Plasma prolactin during lithium treatment","volume":"3","author":"Lanng Nielsen","year":"1977","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.eclinm.2024.102581_bib61","first-page":"163","article-title":"GABAergic control of hypophyseal gonadotropic function and prolactin. Demonstration by valproic acid]","volume":"14","author":"Giroud","year":"1985","journal-title":"J\u00a0Gynecol Obstet Biol Reprod"},{"key":"10.1016\/j.eclinm.2024.102581_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109607","article-title":"Topiramate in the treatment of antipsychotic-induced hyperprolactinemia","volume":"138","author":"Huang","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.eclinm.2024.102581_bib63","series-title":"StatPearls","author":"Cooper","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102581_bib64","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized clinical trial","volume":"77","author":"Correll","year":"2020","journal-title":"JAMA Psychiatr"},{"key":"10.1016\/j.eclinm.2024.102581_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211034019","article-title":"The role of lumateperone in the treatment of schizophrenia","volume":"11","author":"Syed","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib66","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00213-015-3922-1","article-title":"ITI-007 demonstrates brain occupancy at serotonin 5-HT(2)A and dopamine D(2) receptors and serotonin transporters using positron emission tomography in healthy volunteers","volume":"232","author":"Davis","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.eclinm.2024.102581_bib67","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial","volume":"178","author":"Calabrese","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib68","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14739","article-title":"The efficacy of lumateperone in patients with bipolar depression with mixed features","volume":"84","author":"McIntyre","year":"2023","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib69","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials","volume":"48","author":"Wu","year":"2022","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.eclinm.2024.102581_bib70","article-title":"Illuminating hope for mental health: a drug review on lumateperone","volume":"15","author":"Tarzian","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.eclinm.2024.102581_bib71","first-page":"70","article-title":"Impact of lurasidone on metabolic parameters and prolactin levels based on differences of psychiatric diagnosis, dosage, and introducing methods: an observational study","volume":"19","author":"Nakamura","year":"2022","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.eclinm.2024.102581_bib72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jad.2013.10.040","article-title":"Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"155","author":"Citrome","year":"2014","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.eclinm.2024.102581_bib73","doi-asserted-by":"crossref","first-page":"207","DOI":"10.9758\/cpn.2023.21.1.207","article-title":"Mild decrease in blood glucose levels may predict efficacy of antipsychotic lurasidone","volume":"21","author":"Nagamine","year":"2023","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.eclinm.2024.102581_bib74","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1176\/appi.ajp.2016.16040394","article-title":"Down-regulation of SIRT1 gene expression in major depressive disorder","volume":"173","author":"Luo","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib75","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s12640-022-00480-z","article-title":"Activation of SIRT-1 signalling in the prevention of bipolar disorder and related neurocomplications: target activators and influences on neurological dysfunctions","volume":"40","author":"Rajkhowa","year":"2022","journal-title":"Neurotox Res"},{"key":"10.1016\/j.eclinm.2024.102581_bib76","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archpsyc.1989.01810030049007","article-title":"Reduction of prefrontal cortex glucose metabolism common to three types of depression","volume":"46","author":"Baxter","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib77","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1017\/S0033291722002392","article-title":"Functional and structural brain differences in bipolar disorder: a multimodal meta-analysis of neuroimaging studies","volume":"52","author":"Chen","year":"2022","journal-title":"Psychol Med"},{"key":"10.1016\/j.eclinm.2024.102581_bib78","doi-asserted-by":"crossref","first-page":"104758","DOI":"10.1016\/j.neubiorev.2022.104758","article-title":"Insulin resistance in depression: a large meta-analysis of metabolic parameters and variation","volume":"139","author":"Fernandes","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.eclinm.2024.102581_bib79","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/jphp.12209","article-title":"Interactions between valproic acid and quetiapine\/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring","volume":"66","author":"Vella","year":"2014","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib80","doi-asserted-by":"crossref","first-page":"446.e441","DOI":"10.1016\/j.genhosppsych.2009.06.005","article-title":"Unexpected interaction between quetiapine and valproate in patients with bipolar disorder","volume":"32","author":"Huang","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib81","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hup.869","article-title":"Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder","volume":"22","author":"Winter","year":"2007","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib82","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics","volume":"10","author":"Spina","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.eclinm.2024.102581_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12010013","article-title":"Pharmacogenomic characterization in bipolar spectrum disorders","volume":"12","author":"Fortinguerra","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.eclinm.2024.102581_bib84","first-page":"e8407","article-title":"Efficacy and safety of quetiapine for pediatric bipolar depression: a systematic review of randomized clinical trials","volume":"12","author":"Srinivas","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.eclinm.2024.102581_bib85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.12740\/PP\/OnlineFirst\/92740","article-title":"Clinical picture and treatment of bipolar affective disorder in children and adolescents","volume":"54","author":"Cichon","year":"2020","journal-title":"Psychiatr Pol"},{"issue":"Suppl 4","key":"10.1016\/j.eclinm.2024.102581_bib86","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.eclinm.2024.102581_bib88","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bdi.12556","article-title":"The International Society for Bipolar Disorders Task Force report on pediatric bipolar disorder: knowledge to date and directions for future research","volume":"19","author":"Goldstein","year":"2017","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.eclinm.2024.102581_bib89","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/00048674211009620","article-title":"Monitoring of metabolic side-effects in children and adolescents prescribed antipsychotic medication: a systematic review","volume":"55","author":"Mead","year":"2021","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102581_bib90","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12916-019-1346-1","article-title":"The effects of antipsychotic medications on microbiome and weight gain in children and adolescents","volume":"17","author":"Bretler","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2024.102581_bib91","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ijcard.2015.09.070","article-title":"HbA1c and all-cause mortality risk among patients with type 2 diabetes","volume":"202","author":"Li","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.eclinm.2024.102581_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pscychresns.2004.06.002","article-title":"Volume reduction of the amygdala in patients with schizophrenia: a magnetic resonance imaging study","volume":"132","author":"Niu","year":"2004","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.eclinm.2024.102581_bib93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/YIC.0000000000000047","article-title":"Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects","volume":"30","author":"Cabaleiro","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.eclinm.2024.102581_bib94","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/7854_2010_45","article-title":"Antipsychotics and metabolics in the post-CATIE era","volume":"4","author":"Meyer","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.eclinm.2024.102581_bib95","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.eclinm.2024.102581_bib96","article-title":"Racial\/ethnic differences in the pharmacokinetics of antipsychotics: focusing on east asians","volume":"12","author":"Lin","year":"2022","journal-title":"J\u00a0Pers Med"},{"key":"10.1016\/j.eclinm.2024.102581_bib97","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4088\/JCP.08m04267","article-title":"The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia","volume":"70","author":"Meyer","year":"2009","journal-title":"J\u00a0Clin Psychiatry"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024001603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024001603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T21:51:00Z","timestamp":1760737860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024001603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":96,"alternative-id":["S2589537024001603"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102581","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of antipsychotics and mood stabilisers on metabolism in\u00a0bipolar disorder: a network meta-analysis of randomised-controlled trials","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102581"}}